MapLight’s ML-007C-MA Meets Primary Endpoint in Phase 2 Schizophrenia Trial
MapLight's ML-007C-MA met its primary endpoint in Phase 2 schizophrenia trial, showing significant PANSS improvement and cognitive benefits with...
SaaS Platforms Gain Traction in Clinical Trials Despite Spreadsheet Reliance
87% of clinical trial sites use decentralized elements, yet most still rely on spreadsheets. SaaS platforms are closing that...
The Genetic Trial Diversity Problem Is Now a Site Operations Problem
A 99,783-person multi-ancestry Parkinson's study just exposed a critical enrollment gap: GBA1 and LRRK2 trials run almost exclusively in...
NIH Grant Terminations Expose Structural Crisis at Clinical Research Sites
383 NIH-funded clinical trials terminated, exposing structural pressures on research sites managing funding cuts and protocol complexity simultaneously.
The Oral Revolution in Inflammatory Skin Disease: What Povorcitinib’s Phase 3 Design Reveals About the Next Wave of Dermatology Trials
Incyte's STOP-HS1/2 trials (1,227 patients) show how JAK1-selective design and rigorous RCT methodology are reshaping dermatology's clinical trial landscape.
argenx to Acquire Forte Biosciences for $2.2 Billion, Gains FB102 Antibody
argenx acquires Forte Biosciences for $2.2 billion to gain FB102 antibody, an anti-CD122 treatment showing Phase 1b efficacy in...
WCG CenterWatch 2025 Report Shows AI Adoption Remains Uneven Across Clinical Research
WCG CenterWatch 2025 Report reveals where AI adoption stands in clinical research, showing implementation gaps between aspiration and execution.
WCG Report: 92% of Clinical Trial Organizations Plan AI Investment Within Two Years
92% of clinical trial organizations plan AI investment within two years, though only one-third currently use it meaningfully across...
The LITMUS Study Just Changed How You Should Design Your MASLD Trial Endpoints
LITMUS Imaging Study validates imaging and serum biomarkers for MASLD fibrosis—here's what it means for endpoint strategy in your...
CHMP Recommends Marketing Authorization for Obicetrapib in EU
CHMP recommends marketing authorization for obicetrapib in the EU, with Phase 3 trials showing up to 50% LDL-C reductions...